SYGNIS Pharma AG – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 2 PAGES: 47

More Info
									SYGNIS Pharma AG – Product Pipeline Review




    SYGNIS Pharma AG – Product Pipeline Review – H2
                        2011


                                                                                          Reference Code: GMDHC02089CDB
                                                                                                 Publication Date: DEC 2011




SYGNIS Pharma AG – Product Pipeline Review – H2 2011                                      GMDHC02089CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
SYGNIS Pharma AG – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
SYGNIS Pharma AG Snapshot .......................................................................................................................................................... 5
    SYGNIS Pharma AG Overview ..................................................................................................................................................... 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
SYGNIS Pharma AG – Research and Development Overview .......................................................................................................... 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
SYGNIS Pharma AG – Pipeline Review ............................................................................................................................................. 8
    Pipeline Products by Stage of Development ................................................................................................................................. 8
    Pipeline Products – Monotherapy ................................................................................................................................................. 9
SYGNIS Pharma AG – Pipeline Products Glance ............................................................................................................................ 10
    SYGNIS Pharma AG Clinical Stage Pipeline Products................................................................................................................ 10
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 10
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 11
    SYGNIS Pharma AG – Early Stage Pipeline Products ................................................................................................................ 12
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 12
SYGNIS Pharma AG – Drug Profiles ............................................................................................................................................... 13
    AX200 .......................................................................................................................................................................................... 13
        Product Description................................................................................................................................................................. 13
        Mechanism of Action ............................................................................................................................................................... 13
        R&D Progress ......................................................................................................................................................................... 13
    AX201 .......................................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    KIBRA Modulators ....................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    SY300 .......................................................................................................................................................................................... 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
SYGNIS Pharma AG – Pipeline Analysis ......................................................................................................................................... 18
    SYGNIS Pharma AG – Pipeline Products by Therapeutic Class ................................................................................................. 18
    SYGNIS Pharma AG - Pipeline Products By Target .................................................................................................................... 20
    SYGNIS Pharma AG – Pipeline Products by Route of Administration......................................................................................... 21
    SYGNIS Pharma AG – Pipeline Products by Molecule Type ...................................................................................................... 22
SYGNIS Pharma AG – Recent Pipeline Updates ............................................................................................................................ 23
SYGNIS Pharma AG - Dormant Projects ......................................................................................................................................... 24



SYGNIS Pharma AG – Product Pipeline Review – H2 2011                                                                                    GMDHC02089CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
SYGNIS Pharma AG – Product Pipeline Review




SYGNIS Pharma AG – Locations And Subsidiaries ......................................................................................................................... 25
    Head Office.................................................................................................................................................................................. 25
    Other Locations & Subsidiaries ................................................................................................................................................... 25
Company's Recent Developments ................................................................................................................................................... 26
    SYGNIS Pharma AG, Recent Developments .............................................................................................................................. 26
         Mar 24, 2009: SYGNIS Wins US Patent For AX200 For Treatment Of Stroke ....................................................................... 26
         Dec 22, 2010: SYGNIS Announces Data Safety Monitoring Board Recommendation For Phase II Study Of AX200 ............ 26
         Mar 22, 2011: SYGNIS Enters Final Stage With Phase II Efficacy Study Of AX200 For Treatment Of Acute Stroke ............. 27
         Sep 17, 2007: SYGNIS’ AX200 Shows Efficacy In Stroke Patients – Phase IIa Results Exceed Expectations ...................... 27
         Sep 15, 2011: SYGNIS Further Streng
								
To top